Treatment of breast cancer with low expression of human epidermal growth factor receptor 2(HER2;HER2-low)has drawn much attention in recent years.With the proven therapeutic effect of trastuzumab deruxtecan(T-DXd)in p...Treatment of breast cancer with low expression of human epidermal growth factor receptor 2(HER2;HER2-low)has drawn much attention in recent years.With the proven therapeutic effect of trastuzumab deruxtecan(T-DXd)in patients with HER2-low(immunohistochemistry[IHC]1+,or IHC2+/in situ hybridization[ISH]-)breast cancer,HER2-low may become a new subtype of targeted therapy for breast cancer.The expert committee formulated this consensus based on the current clinical studies and clinical medication experience.The current consensus is the collaborative work of an interdisciplinary working group,including experts in the fields of pathology and oncology.The purpose of this consensus was to guide the clinical diagnosis and treatment of HER2-low breast cancer,thereby prolonging the overall survival of patients.展开更多
OBJECTIVE:To determine the difference in prevention of chemotherapy-induced fatigue between time-acupointsspace acupuncture(ATAS)administered weekly compared to sham acupuncture and non-acupuncture in patients with ea...OBJECTIVE:To determine the difference in prevention of chemotherapy-induced fatigue between time-acupointsspace acupuncture(ATAS)administered weekly compared to sham acupuncture and non-acupuncture in patients with early breast cancer receiving adjuvant chemotherapy by epirubicine-cyclophosphamide(EC)followed by paclitaxel,as measured by the multidimensional fatigue inventory(MFI)over the previous week and Visual Analogue Scale measuring fatigue(VAS-F),and to evaluate the effects of ATAS on selfreported neuropathy pain,sleep,anxiety and depression.METHODS:In this multicenter clinical trial,we have randomized patients into 3 groups:ATAS,Sham and nonacupuncture with an unequal randomization of 2∶1∶1.A cloud related electronical clinical report form and smartphone platform was established for data entry.Patients with a history of stageⅠ-Ⅲbreast cancer scheduled to receive adjuvant chemotherapy.Acupuncture will be delivered once a week during chemotherapy with VAS-F evaluation.In order to qualify and quantify the mechanism of fatigue induced by chemotherapy with or without acupuncture,an evaluation of immune profiling was incorporate in this study.RESULTS:The presence and seriousness of chemotherapy-induced fatigue should be considered in therapeutic programs for early breast cancer treatment.Fatigue induced by adjuvant chemotherapy in patients with breast cancer remains a major concern affecting the quality of life significantly.Unfortunately,we do not have effective pharmacological interventions yet.And clinical trials of acupuncture in preventing chemotherapyinduced fatigue in patients with early breast cancer have not been reported.CONCLUSION:The findings of the trial will allow us to determine the effects of acupuncture treatment approach.We will also be able to confirm whether ATAS is better than sham acupuncture and non-acupuncture treatments.展开更多
文摘Treatment of breast cancer with low expression of human epidermal growth factor receptor 2(HER2;HER2-low)has drawn much attention in recent years.With the proven therapeutic effect of trastuzumab deruxtecan(T-DXd)in patients with HER2-low(immunohistochemistry[IHC]1+,or IHC2+/in situ hybridization[ISH]-)breast cancer,HER2-low may become a new subtype of targeted therapy for breast cancer.The expert committee formulated this consensus based on the current clinical studies and clinical medication experience.The current consensus is the collaborative work of an interdisciplinary working group,including experts in the fields of pathology and oncology.The purpose of this consensus was to guide the clinical diagnosis and treatment of HER2-low breast cancer,thereby prolonging the overall survival of patients.
基金Supported by PreciMed Platform Europe,a Financial Support from France Ruban Rose,the Pilot Clinical Study at Kunming Site was Granted By Yunnan Provincial Science and Technology Department Funding(No.2018IA059)。
文摘OBJECTIVE:To determine the difference in prevention of chemotherapy-induced fatigue between time-acupointsspace acupuncture(ATAS)administered weekly compared to sham acupuncture and non-acupuncture in patients with early breast cancer receiving adjuvant chemotherapy by epirubicine-cyclophosphamide(EC)followed by paclitaxel,as measured by the multidimensional fatigue inventory(MFI)over the previous week and Visual Analogue Scale measuring fatigue(VAS-F),and to evaluate the effects of ATAS on selfreported neuropathy pain,sleep,anxiety and depression.METHODS:In this multicenter clinical trial,we have randomized patients into 3 groups:ATAS,Sham and nonacupuncture with an unequal randomization of 2∶1∶1.A cloud related electronical clinical report form and smartphone platform was established for data entry.Patients with a history of stageⅠ-Ⅲbreast cancer scheduled to receive adjuvant chemotherapy.Acupuncture will be delivered once a week during chemotherapy with VAS-F evaluation.In order to qualify and quantify the mechanism of fatigue induced by chemotherapy with or without acupuncture,an evaluation of immune profiling was incorporate in this study.RESULTS:The presence and seriousness of chemotherapy-induced fatigue should be considered in therapeutic programs for early breast cancer treatment.Fatigue induced by adjuvant chemotherapy in patients with breast cancer remains a major concern affecting the quality of life significantly.Unfortunately,we do not have effective pharmacological interventions yet.And clinical trials of acupuncture in preventing chemotherapyinduced fatigue in patients with early breast cancer have not been reported.CONCLUSION:The findings of the trial will allow us to determine the effects of acupuncture treatment approach.We will also be able to confirm whether ATAS is better than sham acupuncture and non-acupuncture treatments.
